- Generic drugmakers gain key victory in ‘skinny label’ patent caseThe Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.BioPharma Dive · 1mo ago↗ source
- Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.BioPharma Dive · 1mo ago↗ source
- Alnylam, Inceptive ink AI deal potentially worth $2BThe RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.BioPharma Dive · 1mo ago↗ source